研究单位：[1]Waterstone Pharmaceutical (Wuhan) Co., LTD.[2]Peking University People''s Hospital,Beijing,Beijing,China,100000[3]Peking University Shougang Hospital,Beijing,Beijing,China,100000[4]Zhongshan Hospital, Xiamen University,Xiamen,Fujian,China,361000[5]The Affiliated Hospital of Hebei University,Baoding,Hebei,China,071000[6]Hebei Traditional Chinese Medicine Hospital,Shijiazhuang,Hebei,China,050000[7]The Second Hospital of Hebei Medical University,Shijiazhuang,Hebei,China,050000[8]The First Hospital of Qiqihar,Qiqihar,Heilongjiang,China,161000[9]The First People''s Hospital of Nanyang City,Nanyang,Henan,China,473000[10]Puyang Oilfield General Hospital,Puyang,Henan,China,457000[11]Shiyan Taihe Hospital,Shiyan,Hubei,China,442000[12]Wuhan No.4 Hospital,Wuhan,Hubei,China,430000[13]Zhuzhou Central Hospital,Zhuzhou,Hunan,China,412000[14]Affiliated Hospital of Inner Mongolia Medical University,Hohhot,Inner Mongolia,China,010000[15]Sir Run Run Hospital, Nanjing Medical University,Nanjing,Jiangsu,China,210000[16]The Second Affiliated Hospital of Nanjing Medical University,Nanjing,Jiangsu,China,210000[17]The Affiliated Hospital of Nantong University,Nantong,Jiangsu,China,226000[18]Shenyang Central Hospital, affiliated to Shenyang Medical College,Shenyang,Liaoning,China,110000[19]General Hospital of Ningxia Medical University,Yinchuan,Ningxia,China,750000[20]The First People''s Hospital of Tancheng County,Linyi,Shandong,China,276100[21]Qilu Hospital of Shandong University (Qingdao),Qingdao,Shandong,China,266000[22]Minhang District Central Hospital,Shanghai,Shanghai,China,200000[23]Shanghai First People''s Hospital,Shanghai,Shanghai,China,200000[24]Shanghai No.5 Hospital,Shanghai,Shanghai,China,200000[25]Shanghai Tongji Hospital,Shanghai,Shanghai,China,200000[26]The Second Affiliated Hospital of Tianjin Medical University,Tianjin,Tianjin,China,300000[27]Tianjin People''s Hospital,Tianjin,Tianjin,China,300000
研究目的：
The goal of this clinical trial is to evaluate the efficacy of different doses of WS016(3g, 6g and 12g) orally administered three times a day for 48 hours (acute treatment phase) vs placebo in the treatment of hyperkalemia, and to evaluate the efficacy of WS016(3g, 6g and 12g) orally administered once daily for 12 days ( maintenance treatment phase) vs placebo in maintaining normokalemia in participants have returned to normokalemia after the acute treatment phase.
